Tri Locum Partners’s Ovid Therapeutics OVID Stock Holding History

Tri Locum Partners’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,009	Closed	-$19K	–	75
2022 Q4	$19K	Buy	+10,009	New	+$17.1K	0.01%	66

Other funds holding OVID

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acadian Asset Management

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Tri Locum Partners's OVID Position: Q1 2023 in Review

Tri Locum Partners sold out of Ovid Therapeutics (OVID) in Q1 2023, closing a stake of 10,009 shares — an estimated $19K sold.

Tri Locum Partners first reported a position in OVID in Q4 2022 and held it in 1 quarter. The position peaked at $19K in Q4 2022. 60 funds tracked by Wall St. Rank hold OVID as of Q1 2023.

Tri Locum Partners reported no remaining Ovid Therapeutics position as of Q1 2023 after selling out during the quarter.
Tri Locum Partners sold 10,009 Ovid Therapeutics shares in Q1 2023, an estimated $19K.
Tri Locum Partners first reported a position in Ovid Therapeutics in Q4 2022 and held it in 1 quarter.
Tri Locum Partners's Ovid Therapeutics position peaked at $19K in Q4 2022.
60 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2023.

Based on Tri Locum Partners's 13F filing for Q1 2023, filed 15 May 2023.